An innovative light-activated therapy developed at The Institute of Cancer Research, London, could help detect and treat an aggressive brain cancer type, a new study shows.

A combination of two existing skin cancer drugs and a third experimental drug could lead to a new strategy for treating patients who do not respond to existing therapies, a new study in mice suggests.

Renewed Cancer Research UK funding for Convergence Science Centre at the ICR and Imperial will build on existing partnership by uniting cancer researchers with engineers and physical scientists to tackle cancer’s toughest challenges.